<DOC>
	<DOCNO>NCT00633490</DOCNO>
	<brief_summary>Apatinib tyrosin-inhibitor agent target vascular endothelial growth factor receptor ( VEGFR ) , inhibit tumor angiogenesis . This phase I study aims determine drug 's toxicity find dose level use phase II study solid tumor patient .</brief_summary>
	<brief_title>Study Apatinib Inhibitor Tumor Angiogenesis</brief_title>
	<detailed_description>Apatinib tyrosin-inhibitor agent target VEGFR ( vasoendothelial growth factor receptor ) inhibit tumor angiogenesis . The anti-angiogenesis effect apatinib view preclinical test ( see protocol ) . This phase I clinical study go evaluate toxicity find appropriate dose level use phase II study heavily treat solid tumor patient .</detailed_description>
	<criteria>≥ 18 ≤ 70 year age Histological cytological confirm solid malignant tumor ECOG performance status ≤ 2 Standard regimen fail standard regimen available Life expectancy 3 month Duration last therapy 6 week nitroso mitomycin ; 4 week operation radiotherapy ; 4 week cytotoxic agent growth inhibitor . Laboratory value : hemoglobin ≥ 9.0g/dl , neutrophil ≥ 1.5×10^9/L , platelet ≥ 100×10^9/L , ALT ≤ 2.5 x upper limit normal ( ULN ) , AST ≤ 2.5 x ULN , serum bilirubin ≤ 1.5 x ULN , serum creatine ≤ 1.5 x ULN , creatinine clearance rate ≥ 50ml/min , PT , APTT , TT , Fbg normal Pregnant lactate woman Any factor influence usage oral administration Evidence CNS metastasis History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix Intercurrence one following : hypertension , coronary artery disease , arrhythmia heart failure Receiving therapy thrombolysis anticoagulation Abuse alcohol drug Allergy ingredient agent two kind food drug Less 4 week last clinical trial Disability serious uncontrolled intercurrence infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Toxicity</keyword>
	<keyword>Efficacy</keyword>
</DOC>